Hans Bishop gets a $287M payday as Juno execs see windfall fortunes — with a $922M payoff for Arch
In every big biotech buyout the big winners are the shareholders and every top executive at the company. And Juno Therapeutics is no exception.
Top earners garnered the most cash, starting with CEO Hans Bishop.
Bishop’s stock in the company is worth $205 million, with an additional set of vested and unvested options registering $68 million and another $8.6 million in restricted shares. That’s a $281.6 million payday, plus another two years salary — $1.3 million cash — to get through the transition. There’s also covered COBRA and $3.4 million for his golden parachute taxes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.